With improvements in care over time it becomes harder to improve clinical outcomes in those conditions where cure rates are high. The focus of research can thus turn to the so-called non-inferiority trial: where the main aim is not to improve clinical outcome, but instead to provide evidence of a lack of difference, whilst other issues, such as cost or toxicity, are improved. The interpretation of such trials is not always straightforward. The burden of proof is reversed compared to a traditional superiority trial, and this means that many of the statistical safeguards, such as significance and intention-to-treat, which act as restraints from an overhasty adoption of a new therapy, may actually work in the opposite fashion. The issues regarding non-inferiority and equivalence trials are considered, and their interpretation discussed.
The general thrust of medical research is to improve outcomes, either by offering new insights into a condition, or by identifying more efficacious therapies for patients, or subsets of patients. New therapies are adopted if they can be demonstrated to be an improvement on current care. The salutary lesson of so-called S-A-B (Same as Before) therapy (Wheatley, 2002) demonstrates the importance of the randomised controlled trial in providing evidence of these advances. Trials where the aim is to demonstrate an improvement in outcome are typically termed superiority trials -these are the trials which are both most common in the literature and the most familiar, and the issues such as intention-to-treat, allocation concealment and reduction of bias (for example by blinding) are well rehearsed in many courses and textbooks.
However, as clinical outcomes have improved, so the scope for further advances in some conditions has become more limited. As a result, attention has turned to improving aspects, such as toxicity or quality of life, while clinical outcomes are not unduly compromised, such as recent trials in acute promyelocytic leukaemia (APL) (Burnett et al, 2015) . These, termed non-inferiority trials, do not, as in the classical superiority trial, aim to provide evidence of improved outcomes, but rather aim to show that the new therapy is no worse than the existing treatment (US Food and Drug Administration, 2010) . In this article we review the areas where a non-inferiority trial may be valuable, and also some of the issues in designing and interpreting such trials.
Why look for non-inferiority?
At first sight it may seem counterintuitive to look for a treatment that is not much worse than current therapy. And indeed, in many cases this does seem an inappropriate approach. Why change therapy without any evidence of improvement? However, there are situations where such a change might be made. For conditions where the outcome is good (e.g., APL) and where there are regimens available which do not include any chemotherapy, delivering the same outcomes as before but without the toxicity associated with chemotherapy would be considered an advance (Burnett et al, 2013; Lo-Coco et al, 2013; Burnett et al, 2015) . Delivering the same clinical outcome with lower doses or fewer courses of treatment, or with less associated cost would all be considered improvements. In all of these examples, even if outcomes remain the same, the experimental therapy would be preferable, be it on grounds of tolerability, patient satisfaction, or cost (or indeed a combination of the three). Under these circumstances a non-inferiority trial would be an appropriate design. The one-sided nature of the hypothesis -that the new therapy will be preferable if it is either better or no worse than existing therapy -reflects the underlying decision to be made. The two-sided analogue of the non-inferiority trial is the equivalence trial, where the aim is that one is looking to rule out a meaningful difference between the two treatments. Sometimes non-inferiority trials can be referred to as equivalence trials, but strictly speaking they are not: superiority is considered acceptable, as it favours the new treatment, but the equivalence hypothesis would not be satisfied. A true equivalence trial may be used to demonstrate bio-equivalence (i.e. that two different formulations of a drug are, to all intents and purposes, identical; Weise et al, 2012) . As pointed out by D'Agostino et al (2003) in their historical survey, it was these principles which were adapted to form the statistical basis for non-inferiority trials.
What makes non-inferiority different?
There is a fundamental difference in approach in a noninferiority trial. In a typical superiority trial, given a nonsignificant result there is insufficient evidence that there is a difference between the treatments. But, simply having a nonsignificant result is not enough to conclude non-inferiority or equivalence. In a non-inferiority trial, one needs evidence of a lack of difference, as opposed to lack of evidence of any difference. Not significant is not synonymous with not different, or, as this concept is more commonly put, "Absence of evidence is not evidence of absence" (Altman & Bland, 1995) . To take a simple example, given a small trial of 10 vs. 10 patients, a response rate of 3/10 vs. 7/10 gives a P-value of 0Á18 using a Fisher exact test; so not significant. But one would not be happy to commit to using the treatment with a 30% response rate in preference to the one with a 70% response rate. There is insufficient evidence of any difference, but likewise, not enough evidence to be happy concluding that any difference in response rate is too small to be of material importance.
It is for this reason that non-inferiority trials are described as trials "through the looking glass" (Schumi & Wittes, 2011) . And this is an attractive metaphor. The null hypothesis of no difference between treatments, which is used in a superiority trial, is clearly not the default position for noninferiority; and many of the notions of bias reduction used in superiority trials need to be rethought. Importantly, however, the concept of non-inferiority and statistical significance need to be unlinked. Non-significance is not enough to conclude non-inferiority, as we saw above; but neither does significance rule out non-inferiority.
The underlying issue here is that non-inferiority in this context does not mean "no worse" -because that would be virtually analogous to superiority -but rather "not appreciably worse". The key word in this description is "appreciably", and this is a feature of the trial design. A non-inferiority trial defines non-inferiority in terms of a "non-inferiority margin". For example, if current treatment has a response rate of 70%, and one sets a non-inferiority margin of 10%, then a response rate above 60% for the experimental therapy is considered acceptable, but to truly conclude non-inferiority one must be able to demonstrate that a response rate below 60% is unlikely. In other words, interpretation is based upon the effect size and confidence intervals and not P-values. In the example above, the lower bound of the confidence interval must exceed 60%. Typically, significance in a non-inferiority trial is set at 2Á5% one-sided, which is directly analogous to the 2-sided 5% significance level in a superiority trial. In both cases, one can use 95% confidence intervals to estimate treatment effects and the degree of uncertainty. In a superiority trial, significance is achieved when the 95% confidence interval does not include the point of no effect. For non-inferiority, the 95% confidence interval should not include the pre-specified margin of non-inferiority. This can be graphically represented as in Fig 1. The advantage of interpretation using confidence intervals is shown in Fig 2, where the event of interest is response to treatment. Suppose we set a margin of non-inferiority as an odds ratio of 1Á15 (where an odds ratio>1 is taken to be worse for the new treatment; equivalent here to a 3Á5% reduction in event rate). Then while in Fig 2A, all results are perfectly null, only Example 4 has results incompatible with an odds ratio of 1Á15. Conversely, in Fig 2B, although in all cases Example 2 has worse outcomes than Example 1, in Example 4, the results are again incompatible with an odds ratio of 1Á15 or above. Only in Example 4 in both cases, can one conclude non-inferiority with a margin of 15% in odds ratio.
Thus, it can be seen that the interpretation of a non-inferiority trial may be different from a superiority trial: in Fig 2B , Example 4 shows a statistically significant difference, but at the same time evidence that the treatment is "noninferior" in the sense that the preselected minimum important difference is ruled unlikely. The use of P-values alone would lead to wrongly interpreting the results of the various trials. Different conclusions that can be drawn for superiority and non-inferiority trials. The dotted line indicates the non-inferiority margin and the vertical bar indicates the point of no effect. OR, odds ratio; 95% CI, 95% confidence interval.
Design challenges in non-inferiority trials
In a superiority trial, there are a number of important approaches that are often described as designed to minimise bias. Some of these carry directly forward to a non-inferiority trial: randomisation is important because one is looking to reduce selection bias, and this is equally important whether one is looking to prove superiority or non-inferiority. However, other approaches, such as intention-to-treat, are less clear-cut. By including all patients randomised, irrespective of compliance, one does get similar groups to compare, but non-compliance with allocation will tend to reduce the estimate of treatment effect; in other words, intention-to-treat is conservative (Gupta, 2011) . This is fine for superiority trials: when one sees a difference one can be sure that it is really there; but for non-inferiority trials a real difference may be masked. An example analogous to the one presented by Hills et al (2003) will demonstrate the problem. Imagine a new maintenance treatment to be given at the end of chemotherapy for a condition. The randomisation to new or current treatment is performed at diagnosis with 600 patients in each arm. However, two thirds of all patients do not reach maintenance therapy, and of these 400 patients per arm, suppose 320 die, reflecting the fact that patients who are not fit for maintenance will generally be those with poor outcomes (including early mortality). Of the remaining 200 patients per arm, only half are fit for the new maintenance therapy, and the others get the current control arm. If the control treatment is given then the death rate is 45%; but if the new experimental treatment is given then the death rate is 60%. Table I shows the schematic of the patient flow, where the overall event rate is 425/600 (71%) vs. 410/600 (68%), giving a rough Peto odds ratio of 1Á13 (95% confidence interval 0Á88-1Á44, P = 0Á3). In terms of raw proportions, the 95% confidence interval for the difference in proportions runs from À3% to 8%; so if the non-inferiority margin was set above 8% one would conclude non-inferiority had been met. But among the people who could draw either arm, the difference is 60/100 vs. 45/100, i.e. a 15% difference, odds ratio 1Á82 (1Á05-3Á17) P = 0Á03; i.e. significantly worse, and it is certainly not possible to conclude that the new therapy is non-inferior to control. Clearly, it is important when considering non-inferiority to minimise any aspects of design that might dilute treatment effect, in stark contrast to proving superiority, when such issues would be conservative. In the example, the randomisation should take place after chemotherapy and immediately before maintenance and the number of patients required will be calculated based upon the difference in survival from the start of maintenance that one wishes to rule out. This example demonstrates that use of intention to treat analyses can potentially artificially reduce any treatment effect when there are issues with compliance or adherence and, as in this case, potentially narrow the confidence intervals. This sort of bias would work against the new treatment in a superiority trial -one is putting in large amounts of evidence that there is no difference; but in a non-inferiority trial, it can lead to a mistaken conclusion that there is no material difference. For this reason, non-inferiority designs need to be interpreted in the light of compliance and adherence to therapy, rather in the same way as one looks for acceptable toxicity in a clinical trial. Because the burden of proof is reversed (one is effectively having to prove a lack of effect and not an effect) any biases introduced should tend to be anti-conservative (i.e. tending to overestimate any difference) and biased against the new treatment -in that way, if non-inferiority is achieved, one knows that the new treatment definitely performs better than the non-inferiority margin. For this reason, per protocol analyses, which generally are anti-conservative, are important in this context. Additionally, compliance needs to be maximised by making the point of randomisation as close to treatment divergence as possible, thus reducing as far as possible dilution effects, and selection biases resulting from differential compliance/adherence.
The non-inferiority margin and control groupwhat is "no worse than"?
In a "successful" non-inferiority trial, one will end up with a conclusion that a new treatment is non-inferior to an existing treatment. But, as has been pointed out, the meaning of noninferior in this context is that it is not meaningfully worse and this requires the difference to be within a certain margin. The choice of this margin is important: it needs to reflect the maximum difference one is prepared to accept. For example, if one is testing two treatments for non-inferiority the margin should be smaller than the benefit of one treatment versus no treatment at all. Otherwise, one could have the situation where an ineffective treatment is ruled non-inferior to an effective one. The precise size of any non-inferiority margin will vary from situation to situation, but generally speaking it should be a fraction, e.g. one half, of the lower end of the 95% confidence interval of the treatment effect seen versus control or placebo (Schumi & Wittes, 2011; Fleming, 2008) .
Typically, when designing a non-inferiority trial, the assumption is that the two treatments are equally good, but one wants to rule out a certain size of disbenefit. However, the sample size for a non-inferiority trial crucially depends on this assumption. If one wants to rule out a 5% difference in survival, then the numbers required vary hugely depending on whether one's initial belief is that the two treatments are equally good, or that one or other is better.
What is further important is that non-inferiority is not transitive (Fleming, 2008) . In superiority trials, if treatment B is superior to treatment A and treatment C is superior to treatment B, then it is reasonable to conclude that C is superior to A (assuming of course that the settings are comparable). However, if one sets a non-inferiority margin of 10%, then if B is non-inferior to A, it is possible that outcomes with B are 7% worse than with A; likewise if C is non-inferior to B then outcomes with C could again be 7% worse than with B, and therefore 14% worse than with treatment A. So despite the results of two non-inferiority trials, it is not correct to assume that all treatments are equally valid.
As important as the inferiority margin is the choice of comparator: in the same way as a superiority trial should compare a new treatment against the current standard of care (as that is the evidence required to change treatments), so too should a non-inferiority trial -one needs to test the new treatment against the best one has to offer, not just of efficacy grounds but also toxicity -comparing against too high a dose of current drug is likely to bias any comparison of toxicity in favour of the new treatment.
Choice of endpoint
Perhaps one of the most important aspects of non-inferiority trials lies in the use of the endpoint. Generally, as with superiority trials, for clinical non-inferiority one could look at disease control (measured for example in terms of remission, minimal residual disease, relapse/recurrence, progression-free survival or time to further treatment) or overall survival. Both approaches can lead to unreliable conclusions. In a condition that is readily salvageable, there may be large differences in disease control, but, because of effective salvage, survival is similar. So a non-inferiority result on survival may mask a number of issues regarding salvage therapy. The aim is to get outcomes that are no worse with less cost to the patient (in terms of toxicity and quality of life) or exchequer. A new treatment may be non-inferior on survival, but if relapse or progression rates are higher, then the survival result may mask the additional toxicity caused by the increased use of salvage therapy. Conversely, using relapse/recurrence in a non-inferiority trial of less intensive versus more intensive monitoring may be misleading. The less intensive monitoring will pick up relapses later and therefore have better relapse-free survival, and longer time to further treatment -but those relapses may be less salvageable, leading to worse survival.
Conclusions
The interpretation of a non-inferiority trial is subtly different from that of a superiority trial, although both are well served by considering treatment effects and confidence intervals rather than dichotomising P-values. In particular, non-significance is not the same as non-inferiority; there needs to be positive evidence of lack of (adverse) effect as opposed to lack of evidence of difference. Many of the features of trial design that we take for granted need to be turned on their head: approaches in superiority trials are designed, when bias cannot be eliminated, to be biased against the new therapy. In particular, non-compliance and non-adherence penalise the experimental therapy in a superiority trial -but work in favour of non-inferiority. In all cases any biases introduced need to act against the hypothesis one is trying to prove -so that if the hypothesis is demonstrated to be true, it cannot be explained away by the experimental design. Ultimately, the aim of any clinical trial is to change practice -in interpreting the results, one must ask whether one is convinced that the evidence is strong enough to change what one does. For a non-inferiority trial, one must be convinced that the patient is not going to be materially disadvantaged compared to current practice. In cases such as APL, where outcomes with less intensive therapy appear better (Lo-Coco et al, 2013) , this is a relatively simple decision; when the results show a small but significant worsening in outcomes the decision is less clear-cut and more multi-factorial. To what extent is one willing to accept a slight worsening in outcome for greater quality of life/less cost/less toxicity? With the potential for an increase in non-inferiority trials, thought should be given to the presentation of results in terms of acceptable loss of efficacy for other gains, in order to allow a meaningful interpretation of the results and discussion with healthcare providers and, most importantly, patients.
